Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 4Leukemia, Myelomonocytic, Chronic 2Recurrence 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Leukemia, Erythroblastic, Acute 1Leukemia 1Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies 1Aortic aneurysm, familial thoracic 4 1

Interventions

fludarabine phosphate 34Cyclophosphamide 31Peripheral Blood Stem Cell Transplantation 27Mycophenolic Acid 25Cyclosporine 23Antilymphocyte Serum 23Busulfan 20Tacrolimus 17Radiotherapy 17Filgrastim 17Whole-Body Irradiation 15Methotrexate 15Methylprednisolone 14Melphalan 13Cord Blood Stem Cell Transplantation 12venetoclax 9Cytarabine 8Azacitidine 8fludarabine 5Etoposide 5sargramostim 4Therapeutics 4Sirolimus 4Decitabine 4Clofarabine 4Alemtuzumab 4thymoglobulin 3nilotinib 3merphos 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × quizartinib × Myeloid × Clear all
NCT00462761 2020-05-11

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Daiichi Sankyo

Phase 1 Completed
76 enrolled 12 charts
MyeloidOther hematologic neoplasm

Aortic aneurysm, familial thoracic 4, Leukemia, Erythroblastic, Acute, Leukemia, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡